Ophthalmic pharmaceutical compositions for the treatment of neoangiogenic pathologies of the eye

Abstract

The present invention relates to ophthalmic pharmaceutical compositions comprising Sorafenib, its derivatives or active metabolites, for the treatment and prevention of ocular neoangiogenic pathologies.

1 - 8 . (canceled) 
     
     
         9 . A method of treating ocular neoangiogenic pathologies in a subject in need thereof, comprising administering an ophthalmic pharmaceutical composition comprising Sorafenib, its derivatives or active metabolites to said subject in an amount effective to inhibit said ocular neoangiogenic pathologies. 
     
     
         10 . A method according to  claim 9  for the treatment of ocular neoangiogenic pathologies of the posterior chamber of the eye. 
     
     
         11 . A method according to  claim 9  for the treatment of ocular neoangiogenic pathologies of the retina. 
     
     
         12 . A method according to  claim 9  for the treatment of: proliferative vitreoretinopathies, ROP, retinal vascular pathologies, implications of systemic pathologies for the retina, AMD, diabetic retinopathy, macular oedema, neovascular glaucoma, CNV. 
     
     
         13 . A method according to  claim 9 , comprising the combined treatment with said ophthalmic pharmaceutical composition and with PDT. 
     
     
         14 . A method according to  claim 9 , wherein said composition further comprises VDAs, corticosteroids, angiostatic cortisenes, albendazole, mebendazole, carbonic anhydrase inhibitors (CAI), cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), COX-2 selective inhibitors, inhibitors of iNOS, molecules that interfere with inflammatory mediators, molecules with immunosuppressive action, beta-lactamines (penicillins, cephalosporins), macrolides, tetracyclines, fluoroquinolones, natural polypeptides with antibacterial action and fragments thereof, aptamers able to interfere with the neoangiogenesis pathway, monoclonal antibodies able to interfere with the neoangiogenesis pathway, SiRNAs. 
     
     
         15 . A method according to  claim 9 , wherein said composition is in the form of:
 emulsion, ointment, solid insert, suspension, gel, oily solution, viscosized solution, solution obtained by means of cyclodextrins, liposomes, nanoparticles, micelles, depots.   
     
     
         16 . A method according to  claim 15 , wherein said composition is suitable for topical, intravitreal, subconjunctival, subretinal or periocular administration, for administration by juxtascleral injection, or for administration by retrobulbar injection.